Sanofi reports Q4 IFRS EPS (EUR 0.44), down 117.7%

Reports business EPS EUR 1.66, up 8.2% at CER. Reports Q4 IFRS net sales EUR 10.92B, up 1.8%. Paul Hudson, Sanofi CEO, commented: “2023 marked a critical year on our journey to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. We have delivered another year of strong underlying performance of our core drivers in Specialty Care and Vaccines supported by the outstanding launch execution of Beyfortus, Altuviiio and Tzield. With scientific news flow at an all-time high, pipeline advances and 12 potential blockbusters in late-stage development including amlitelimab, frexalimab and tolebrutinib, our R&D transformation has reached an inflection point on the road to industry leadership in immunology. Looking forward, we remain committed to investing in R&D to fully unlock the value of our pipeline, powered by AI at scale, and continue to focus on our expected launch opportunities such as Dupixent in COPD. At the same time, we are taking steps to become a pure-play biopharma company with more than EUR 10bn sales contribution from Pharma launches by 2030.”